Skip to content

EcoR1 Capital, LLC

Follow

13F filer, CIK 1587114, San Francisco, CA

EcoR1 Capital, LLC reported $2,252,570,642 across 36 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 83.45% of the portfolio.

Accepted , ingested 13F-HR 0000935836-26-000577

Period
2026-09-30
Reported value
$2.25B
Holdings
36
Top 10 weight
83.45%
New
10
Sold out
7

Part of the filer group EcoR1 Capital, LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ANROnew+2,232,000$57M
ERASadded+2,620,000$38.4M
ATTOnew+2,024,010$34.7M
CGONadded+377,592$26.8M
ADRXnew+1,150,000$22.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ORICreduced-3,700,000-$49.8M
LEGNexited-800,000-$23.1M
MBXexited-388,500-$21.4M
RLAYexited-697,948-$13.1M
BBOTreduced-1,933,519-$7.93M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0000935836-26-000577, largest first. % of portfolio is the value over $2,034,163,553, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ZYMEZYMEWORKS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 15,028,079 shares; 2025Q1: 17,259,548 shares; 2025Q2: 22,970,388 shares; 2025Q3: 22,970,388 shares; 2025Q4: 22,970,388 shares; 2026Q1: 22,970,388 shares; 2026Q2: 22,970,388 shares; 2026Q3: 22,970,388 shares 22,970,388$608M29.91%0Timeline
ANABANAPTYSBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,873,448 shares; 2025Q1: 7,880,094 shares; 2025Q2: 7,880,094 shares; 2025Q3: 7,880,094 shares; 2025Q4: 7,880,094 shares; 2026Q1: 7,880,094 shares; 2026Q2: 7,880,094 shares; 2026Q3: 7,880,094 shares 7,880,094$396M19.47%02026-11-18, Form 4: bought 138,093 shares on 2026-11-18 Timeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 772,000 shares; 2026Q1: 1,102,000 shares; 2026Q2: 1,494,300 shares; 2026Q3: 1,871,892 shares 1,871,892$133M6.52%+377,592Timeline
ETONETON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,829,603 shares; 2025Q1: 1,939,288 shares; 2025Q2: 2,030,544 shares; 2025Q3: 2,030,544 shares; 2025Q4: 2,030,544 shares; 2026Q1: 2,171,938 shares; 2026Q2: 2,171,938 shares; 2026Q3: 2,470,920 shares 2,470,920$127M6.25%+298,982Timeline
TRAXFIRST TRACKS BIOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 3,174,519 shares; 2026Q3: 3,174,519 shares 3,174,519$113M5.53%0Timeline
AKTSAKTIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,824,469 shares; 2026Q2: 4,824,469 shares; 2026Q3: 4,824,469 shares 4,824,469$93.9M4.62%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,389,276 shares; 2025Q1: 1,389,276 shares; 2025Q2: 1,389,276 shares; 2025Q3: 1,389,276 shares; 2025Q4: 1,389,276 shares; 2026Q1: 1,389,276 shares; 2026Q2: 1,389,276 shares; 2026Q3: 1,389,276 shares 1,389,276$76.9M3.78%0Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,232,000 shares 2,232,000$57M2.8%newTimeline
LKFTLAKEFRONT BIOTHERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 155,006 shares; 2025Q1: 155,006 shares; 2025Q2: 1,036,945 shares; 2025Q3: 1,667,119 shares; 2025Q4: 1,667,119 shares; 2026Q1: 1,667,119 shares; 2026Q2: 1,667,119 shares; 2026Q3: 1,667,119 shares 1,667,119$49.4M2.43%0Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 900,000 shares; 2026Q2: 330,000 shares; 2026Q3: 2,950,000 shares 2,950,000$43.2M2.13%+2,620,000Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,418,068 shares; 2025Q1: 3,418,068 shares; 2025Q2: 1,618,068 shares; 2025Q3: 6,728,116 shares; 2025Q4: 6,728,116 shares; 2026Q1: 6,728,116 shares; 2026Q2: 6,728,116 shares; 2026Q3: 3,028,116 shares 3,028,116$40.8M2.01%-3,700,000Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,271,342 shares; 2025Q1: 1,271,342 shares; 2025Q2: 1,271,342 shares; 2025Q3: 1,271,342 shares; 2025Q4: 1,271,342 shares; 2026Q1: 1,271,342 shares; 2026Q2: 1,271,342 shares; 2026Q3: 1,271,342 shares 1,271,342$35.4M1.74%0Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,024,010 shares 2,024,010$34.7M1.71%newTimeline
FULCFULCRUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 6,549,866 shares; 2026Q3: 6,803,785 shares 6,803,785$25.2M1.24%+253,919Timeline
ADRXADARX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,150,000 shares 1,150,000$22.9M1.13%newTimeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 100,000 shares; 2026Q2: 735,000 shares; 2026Q3: 835,000 shares 835,000$21.7M1.07%+100,000Timeline
ZBIOZENAS BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 789,500 shares; 2026Q1: 789,500 shares; 2026Q2: 789,500 shares; 2026Q3: 789,500 shares 789,500$21.3M1.05%0Timeline
ETRAELECTRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,700,000 shares 1,700,000$19.1M0.94%newTimeline
ATRAATARA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 532,134 shares; 2025Q1: 573,183 shares; 2025Q2: 573,183 shares; 2025Q3: 573,183 shares; 2025Q4: 573,183 shares; 2026Q1: 99,593 shares; 2026Q2: 1,552,000 shares; 2026Q3: 1,552,000 shares 1,552,000$13.2M0.65%0Timeline
CAPRCAPRICOR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,376,580 shares 1,376,580$13M0.64%newTimeline
XNCRXENCOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,144,767 shares; 2025Q1: 6,144,767 shares; 2025Q2: 6,144,767 shares; 2025Q3: 6,144,767 shares; 2025Q4: 3,251,112 shares; 2026Q1: 2,183,000 shares; 2026Q2: not reported; 2026Q3: 500,000 shares 500,000$12.5M0.61%newTimeline
ODTXODYSSEY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 555,555 shares; 2026Q3: 555,555 shares 555,555$12.3M0.61%0Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,666,667 shares; 2026Q3: 1,666,667 shares 1,666,667$10.5M0.51%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 270,000 shares; 2026Q3: 375,000 shares 375,000$8.89M0.44%+105,000Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 416,700 shares 416,700$8.42M0.41%newTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 235,000 shares; 2026Q3: 235,000 shares 235,000$7.45M0.37%0Timeline
EIKNEIKON THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 732,606 shares; 2026Q2: 732,606 shares; 2026Q3: 855,634 shares 855,634$6.88M0.34%+123,028Timeline
ELOXELOXX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 400,000 shares; 2026Q3: 400,000 shares 400,000$6.12M0.3%0Timeline
AARDAARDVARK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 396,194 shares; 2026Q3: 720,028 shares 720,028$3.79M0.19%+323,834Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,823,126 shares; 2025Q4: 2,823,126 shares; 2026Q1: 2,823,126 shares; 2026Q2: 2,823,126 shares; 2026Q3: 889,607 shares 889,607$3.65M0.18%-1,933,519Timeline
TCGXTCGX ACQUISITION CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 250,000 shares 250,000$3.13M0.15%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,179,715 shares; 2026Q2: 1,179,715 shares; 2026Q3: 679,715 shares 679,715$2.83M0.14%-500,000Timeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 200,000 shares; 2026Q2: 200,000 shares; 2026Q3: 200,000 shares 200,000$2.12M0.1%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 64,303 shares 64,303$863K0.04%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
BMYBRISTOL-MYERS SQUIBB CO COMcall3,500,000$218Mnew
CGONCG ONCOLOGY INC COMMON STOCKcall100$7.09K-561,400

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
LEGNLEGEND BIOTECH CORP800,000$23.1Mshares
MBXMBX BIOSCIENCES INC388,500$21.4Mshares
RLAYRELAY THERAPEUTICS INC697,948$13.1Mshares
PHATPHATHOM PHARMACEUTICALS INC625,000$6.78Mshares
MREOMEREO BIOPHARMA GROUP PLC1,000,000$318Kshares
SRZNWSURROZEN INC4,444$115Kshares
AARDAARDVARK THERAPEUTICS INC14,700$84.7Kcall

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000935836-26-000577 base2026-11-16